Oncternal Therapeutics, Inc.
ONCTDelisted Mar 17, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001260990
Oncternal Therapeutics, Inc. was delisted on Mar 17, 2025; its insiders filed their last Form 4 on Jun 24, 2024; 23 institutions reported holding it in 13F filings for Q3 2024, worth $471.0K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 23
- Q3 2024, −2 vs. previous quarter
- 13F value
- $471.0K
- Reported value at the end of Q3 2024
- Superinvestors holding
- 0
- At the end of Q3 2024
Superinvestors holding ONCT, Q3 2024
No superinvestor reported holding ONCT at the end of Q3 2024.
Latest insider trades
Open-market purchases and sales by Oncternal Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 10, 2024 (view filing) | Apr 8 | 2 days | Wills Robert JamesDirector | PPurchase | +3.09K | $8.96 | +$27.7K | +44.6%10.0K after | |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | Wills Robert JamesDirector | PPurchase | +6.91K | $8.48 | +$58.6K | New position6.91K after | |
| Feb 27, 2024 (view filing) | Feb 23 | 4 days | Hale David FDirector | PPurchase | +714 | $9.04 | +$6.45K | New position714 after | |
| Feb 27, 2024 (view filing) | Feb 23 | 4 days | Hale David FDirector | PPurchase | +266 | $9.04 | +$2.40K | +0.9%29.7K after | |
| Feb 27, 2024 (view filing) | Feb 23 | 4 days | Wills Robert JamesDirector | SSale | −980 | $9.04 | −$8.86K | −100.0%0 after | |
| Jun 14, 2023 (view filing)4:00 PM ET | Jun 12-14 | 2 days | Kaufmann Gunnar F.Chief Scientific Officer | PPurchase | +28.0K | $0.3509 | +$9.82K | +42.0%94.7K after | 2 lots |
| Apr 17, 2023 (view filing)6:00 AM ET | Apr 13-14 | 4 days | Breitmeyer James BChief Executive Officer | PPurchase | +150.0K | $0.2929 | +$43.9K | +322.3%196.5K after | 3 lots |
| Apr 14, 2023 (view filing)6:02 PM ET | Apr 12-14 | 2 days | Yazji SalimChief Medical Officer | PPurchase | +25.0K | $0.288 | +$7.20K | +17.9%164.7K after | 3 lots |
| Apr 14, 2023 (view filing)6:00 AM ET | Apr 12-13 | 2 days | Leavitt Chase C.General Counsel/Secretary | PPurchase | +25.0K | $0.29 | +$7.25K | +30.5%106.9K after | 2 lots |
| Apr 14, 2023 (view filing)6:00 AM ET | Apr 13 | 1 day | Vincent Richard GChief Financial Officer | PPurchase | +30.0K | $0.2987 | +$8.96K | +23.6%156.9K after |
Top 10 13F holders, Q3 2024
The largest institutional positions in Oncternal Therapeutics, Inc. at the end of Q3 2024; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 139,884 | $184.6K | 0.00% | −3,159−2.2% | Reduced |
| Millennium Management LLC | 61,205 | $80.8K | 0.00% | −41,731−40.5% | Reduced |
| BlackRock, Inc. | 39,706 | $52.4K | 0.00% | +39,706 | New |
| Geode Capital Management, LLC | 25,879 | $34.2K | 0.00% | 00.0% | Unchanged |
| Pasadena Private Wealth, LLC | 25,000 | $33.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 17,905 | $23.6K | 0.00% | +700+4.1% | Added |
| Morgan Stanley | 14,152 | $18.7K | 0.00% | −915−6.1% | Reduced |
| Quantum Private Wealth, LLC | 13,187 | $17.4K | 0.01% | −13,715−51.0% | Reduced |
| Virtu Financial LLC | 12,276 | $16.0K | 0.00% | +12,276 | New |
| Tower Research Capital LLC (TRC) | 2,822 | $3.73K | 0.00% | +2,201+354.4% | Added |